Company news from the 01/16/07 news brief

Share this article:
Genizon BioSciences announced a license and collaboration agreement with Pfizer for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights. Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed. Redi-Direct Marketing has acquired New York-based Dialog Group, including the firm’s Healthcare Dialog division, a developer of relationship marketing and communication programs for the pharmaceutical industry. Financial terms of the deal were not disclosed. CMPMedica has acquired MediReach Healthcare Communications, a Shanghai, China, consultancy providing medical and pharmaceutical marketing services to multinational pharmaceutical companies across China, for an initial payment of $1.1 million and as much as $2.75 million contingent on future performance.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union